Good article, thanks for posting. It is tough...tougher again when it is an Aussie bio
Tougher still when there is still no revenue...
Most like to wait longer, wait for proven model via revenue or licensed to GO (eg half way thru P3 or closer to the end of it etc).
There are some options (different pathways) for us though...finally once they get a sense of what drug we have and what it can do....well, chances of a decent funding package will increase.
My thoughts
Good article, thanks for posting. It is tough...tougher again...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.005(2.08%) |
Mkt cap ! $85.73M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $180.4K | 746.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 79748 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 22818 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |